Isomorphic Labs is an AI-first drug design and development company spun out of Google DeepMind in 2021. It uses advanced machine learning — most notably building on the AlphaFold protein-structure system — to design new drug molecules faster and more accurately than traditional methods. The company runs its own wet labs to generate experimental data (chemistry, cellular assays, animal studies) that feed back into its proprietary AI Drug Design Engine (IsoDDE) in a closed loop. It currently partners with major pharmaceutical companies — Eli Lilly, Novartis, and Johnson & Johnson — applying its AI models to their drug programs, while simultaneously advancing an internal pipeline of candidates it intends to take into human trials itself. Headquartered in London, with a research site in Lausanne and a fast-growing US hub in Cambridge, MA, Isomorphic sits at the intersection of deep-learning research, medicinal chemistry, and clinical development, targeting a future where AI designs most new medicines from scratch.